person · Reporting owner

Bilenker Joshua H.

Disclosed activity across 4 companies

Tapewire entity: 40911
SEC CIK: 0001612312

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Gossamer Bio, Inc.GOSS · Entity 6928	Director	June 09, 2022	July 15, 2022
Sana Biotechnology, Inc.SANA · Entity 4870	Director	June 04, 2026	June 05, 2026
ViewRay, Inc.VRAY · Entity 111118	Director · 10% owner	September 13, 2016	September 16, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Gossamer Bio, Inc.

Report date June 09, 2022 · Filed July 15, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.02 · Expires 2032-06-08	Direct	30,000	Reported balance After 2022-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: Award made pursuant to Non-Employee Director Compensation Program. F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Award made pursuant to Non-Employee Director Compensation Program.

F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Sana Biotechnology, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03	Direct	90,000	Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

ViewRay, Inc.

Report date September 13, 2016 · Filed September 16, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,964	Reported balance After 2016-09-13 transaction · row 1 1 source row Row 1 · 2016-09-13 · Grant · Acquired 18,964 · Balance 18,964 F1: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon vesting. 100% of the RSUs shall be fully vested as of the date of grant, however, delivery of the shares will be deferred until the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan.
Common StockSEC Table I · non-derivative	IndirectSee footnote	7,461,923	Reported balance Holding disclosure · report date 2016-09-13 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,461,923 F2: Shares are held by Aisling Capital II, LP ("Aisling"). Aisling Capital Partners, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners LLC ("Aisling Parters"), is the general partner of Aisling GP. The individual managing members ("Aisling Managers") of Aisling Partners are Dennis Purcell, Andrew Schiff, M.D. and Steve Elms. Dr. Bilenker, a member of the board of directors of ViewRay, Inc., is an Operating Partner of Aisling Capital, LLC, an affiliate of Aisling, however voting and dispositive decisions with respect to shares held by Aisling are not made by Dr. Bilenker. Dr. Bilenker disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon vesting. 100% of the RSUs shall be fully vested as of the date of grant, however, delivery of the shares will be deferred until the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan.

F2: Shares are held by Aisling Capital II, LP ("Aisling"). Aisling Capital Partners, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners LLC ("Aisling Parters"), is the general partner of Aisling GP. The individual managing members ("Aisling Managers") of Aisling Partners are Dennis Purcell, Andrew Schiff, M.D. and Steve Elms. Dr. Bilenker, a member of the board of directors of ViewRay, Inc., is an Operating Partner of Aisling Capital, LLC, an affiliate of Aisling, however voting and dispositive decisions with respect to shares held by Aisling are not made by Dr. Bilenker. Dr. Bilenker disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Loxo Oncology, Inc.

Report date February 15, 2019 · Filed February 15, 2019

Section 16 reporting ended · disclosed 2019-02-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-02-15 transaction · row 1 1 source row Row 1 · 2019-02-15 · Disposition to issuer · Disposed 162,707 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy Joshua H. Bilenker,ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018	Reported balance After 2019-02-15 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-02-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-11-14	Direct	Reported balance After 2019-02-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-02-15 · Disposition to issuer · Disposed 27,459 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18	Direct	Reported balance After 2019-02-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-02-15 · Disposition to issuer · Disposed 64,471 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2024-12-18	Direct	Reported balance After 2019-02-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-02-15 · Disposition to issuer · Disposed 318,514 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.69 · Expires 2025-12-15	Direct	Reported balance After 2019-02-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-02-15 · Disposition to issuer · Disposed 142,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2026-12-05	Direct	Reported balance After 2019-02-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-02-15 · Disposition to issuer · Disposed 209,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2027-03-14	Direct	Reported balance After 2019-02-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-02-15 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.88 · Expires 2028-01-03	Direct	Reported balance After 2019-02-15 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-02-15 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.77 · Expires 2029-01-01	Direct	Reported balance After 2019-02-15 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-02-15 · Disposition to issuer · Disposed 128,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 14, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,600	$159.13	$254,602.08	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · nonDerivative · entry 7 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,807 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.41 to $159.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 14, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	10,000	$1.18	$11,840.00	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · nonDerivative · entry 6 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
August 13, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · derivative · entry 11 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,932 Underlying: Common Stock · 10,000 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The options have fully vested and are immediately exercisable. Read SEC document
August 13, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	800	$160.49	$128,388.96	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · nonDerivative · entry 5 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.17 to $160.85 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	3,367	$159.63	$537,463.10	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · nonDerivative · entry 4 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,207 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.13 to $160.07 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	4,233	$158.51	$670,971.98	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · nonDerivative · entry 3 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,574 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.10 to $159.05 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,600	$157.67	$252,268.32	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · nonDerivative · entry 2 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,807 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.99 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 21:23 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	10,000	$1.18	$11,840.00	Disclosure SEC source: 0001567619-18-001205 · doc1.xml · nonDerivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,500	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · derivative · entry 16 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,932 Underlying: Common Stock · 7,500 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F14 · derivative.exercise_date: The options have fully vested and are immediately exercisable. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	800	$182.84	$146,271.04	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 13 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F13 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $182.50 to $183.19 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,300	$181.21	$235,570.01	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 12 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,207 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F12 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $180.93 to $181.92 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,000	$180.08	$180,081.00	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 11 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $179.60 to $180.54 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	2,200	$179.08	$393,977.98	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 10 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $178.60 to $179.49 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	2,200	$178.19	$392,023.06	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 9 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,707 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $177.57 to $178.52 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	7,500	$1.18	$8,880.00	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 8 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,500	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · derivative · entry 15 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,432 Underlying: Common Stock · 7,500 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F14 · derivative.exercise_date: The options have fully vested and are immediately exercisable. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$191.63	$57,489.99	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 7 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $191.63 to $191.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$189.43	$56,829.00	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 6 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,707 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $189.12 to $190.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	802	$188.28	$151,004.49	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 5 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,007 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $188.04 to $188.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	3,698	$187.39	$692,957.50	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 4 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,809 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $186.94 to $187.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,500	$186.38	$279,577.35	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 3 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $185.73 to $186.70 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	900	$184.87	$166,382.82	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 2 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,007 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $184.72 to $185.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 21:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	7,500	$1.18	$8,880.00	Disclosure SEC source: 0001140361-18-032158 · doc1.xml · nonDerivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 09, 2018 Filed Jan 17, 2019 13:06 UTC Amendment	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	7,500	$1.18	$8,880.00	Disclosure SEC source: 0001567619-19-001261 · doc1.xml · nonDerivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: This amended Form 4 is being filed solely to correct the reporting person's ending balance by subtracting the additional 1,700 shares of the Issuer's common stock (the "Additional Shares") that were added inadvertently to the total number of shares held directly by the reporting person. The Additional Shares were included in all the subsequent directly held transactions in the Form 4 filed on July 11, 2018 and the five Forms 4 filed thereafter. As of January 17, 2019, the reporting person directly holds a total number of 162,707 shares of the Issuer's common stock. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,500	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · derivative · entry 19 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,932 Underlying: Common Stock · 7,500 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F16 · derivative.exercise_date: The options have fully vested and are immediately exercisable. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	28,000	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · derivative · entry 18 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,432 Underlying: Common Stock · 28,000 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The options have fully vested and are immediately exercisable. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	9,664	$179.77	$1,737,326.27	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 16 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 Disclosed balance after: 8,000 F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F15 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $179.50 to $180.04 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	11,336	$178.94	$2,028,505.78	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 15 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 Disclosed balance after: 17,664 F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F14 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $178.50 to $179.48 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	430	$180.90	$77,785.50	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 14 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,707 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F13 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $180.85 to $180.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	4,370	$179.37	$783,845.59	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 13 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,137 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F12 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $179.09 to $180.02 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	2,700	$178.81	$482,774.04	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 12 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $178.08 to $179.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	7,500	$1.18	$8,880.00	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 11 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	28,000	$1.18	$33,152.00	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 10 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,500	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · derivative · entry 17 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,432 Underlying: Common Stock · 7,500 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F16 · derivative.exercise_date: The options have fully vested and are immediately exercisable. F17 · balance_after: Option exercises that were previously reported by the Reporting Person were attributed to a single option grant in each prior Form 4 filed by the Reporting Person with the Securities and Exchange Commission. This Form 4 combines two option grants with identical terms and reports the respective option exercises in the aggregate on one row. The shares reported in this column as beneficially owned following the reported transaction represents the outstanding shares underlying both option grants. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	103	$180.34	$18,574.69	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 9 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 Disclosed balance after: 29,000 F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $180.23 to $180.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	3,902	$179.83	$701,709.54	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 8 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 Disclosed balance after: 29,103 F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $179.20 to $180.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	8,763	$178.30	$1,562,416.61	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 7 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 Disclosed balance after: 33,005 F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $178.03 to $179.00 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	8,232	$177.44	$1,460,652.33	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 6 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 Disclosed balance after: 41,768 F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $177.00 to $177.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F7 · balance_after: Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 previously reported as held directly pursuant to Rule 16a-13. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,737	$178.12	$309,389.58	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 5 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,707 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $177.67 to $178.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	3,427	$177.06	$606,769.54	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 4 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,444 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $176.64 to $177.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	2,336	$176.20	$411,606.94	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 3 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,871 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $175.60 to $176.59 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	7,500	$1.18	$8,880.00	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 2 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 08, 2018 Filed Jun 21, 2018 21:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	GiftCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001140361-18-029484 · doc1.xml · nonDerivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,707 Read SEC document
May 15, 2018 Filed May 16, 2018 20:44 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	7,500	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001140361-18-024219 · doc1.xml · derivative · entry 17 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,690 Underlying: Common Stock · 7,500 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: The stock option is immediately exercisable in full, and vests as to 25% of the shares subject to the option on the one-year anniversary of the vesting commencement date, and thereafter as to 1/48th of the shares in equal monthly installments. Read SEC document
May 15, 2018 Filed May 16, 2018 20:44 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,803	$138.89	$250,415.60	Disclosure SEC source: 0001140361-18-024219 · doc1.xml · nonDerivative · entry 15 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,707 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F14 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $138.70 to $139.37 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 15, 2018 Filed May 16, 2018 20:44 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	3,297	$138.35	$456,146.87	Disclosure SEC source: 0001140361-18-024219 · doc1.xml · nonDerivative · entry 14 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,510 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F13 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $137.70 to $138.68 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 15, 2018 Filed May 16, 2018 20:44 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	400	$136.72	$54,688.00	Disclosure SEC source: 0001140361-18-024219 · doc1.xml · nonDerivative · entry 13 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,807 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F12 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $136.60 to $137.08 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 15, 2018 Filed May 16, 2018 20:44 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,000	$135.83	$135,828.00	Disclosure SEC source: 0001140361-18-024219 · doc1.xml · nonDerivative · entry 12 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,207 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $135.55 to $136.47 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 15, 2018 Filed May 16, 2018 20:44 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$134.41	$40,322.01	Disclosure SEC source: 0001140361-18-024219 · doc1.xml · nonDerivative · entry 11 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,207 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $134.32 to $134.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 15, 2018 Filed May 16, 2018 20:44 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	700	$133.11	$93,174.55	Disclosure SEC source: 0001140361-18-024219 · doc1.xml · nonDerivative · entry 10 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.55 to $133.20 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.